TDX Tyrian Fpo

Tyrian Diagnostics Limited (ASX:TDX) announced today the appointment of new board member, Dr Merilyn Sleigh and the resignation of John Martin. Dr. Sleigh joins Tyrian with a background in biological research with CSIRO and is currently a non-executive director of Clover Corporation, Mimetica Pty Ltd and the Rural Industries Research and Development Council. She is also a member of the Federal Government�s Task Force developing a 10 year strategy for the pharmaceutical industry in Australia, and advises CSIRO and the Garvan Institute for Medical Research on research commercialisation. Previously, she was the Managing Director of the antibody therapeutics company EvoGenix Ltd. �The Board is delighted that Merilyn will join us as a non-executive director,� said Roger Amos, Chairman of Tyrian. �She has an impressive track record in the Australian biotech sector and we�re pleased she can bring her corporate growth experience to Tyrian. The appointment of Merilyn together with the recent appointment of Dr Caroline Popper means the Board is now well structured to oversee the Company�s next growth phase in building its diagnostic product pipeline�. TDX also announced the resignation of John Martin from its Board. John has been a director since 2000 and a non-executive director since his departure as Deputy CEO in 2004 to accept a position with Babcock & Brown to build its retirement & aged care platform, resulting in his appointment as Managing Director of B & B Communities. Since then, John has made a valuable contribution in assisting the Board to successfully reposition the Company to take full advantage of its core capabilities. Roger Amos said �I have appreciated John�s unique contribution over the past 18 months or so we have worked together. As the longest serving director he brought considerable insight to the issues the Board has faced in refocusing the Company�s activities.� About Tyrian Diagnostics Tyrian Diagnostics (ASX: TDX) is a diagnostics company with expertise in biomarker discovery and validation and diagnostic test development and a core focus on respiratory and infectious diseases. In addition, Tyrian can partner in alternative fields given its capabilities to work across the entire spectrum of diagnostic test development � from identification and isolation of biomarkers, point-of-need test design, clinical development or field testing to final product. Tyrian�s product pipeline includes: WheatRite� for measuring wheat quality, which is partnered with BayerCropSciences; and a rapid test for active tuberculosis, in collaboration with Becton Dickinson and Company. Additional information about Tyrian Diagnostics can be found at www.tyriandx.com